- Email: [email protected]
5374424 Multivalent FeLV-infected feline vaccine
803
PATENT ABSTRACTS belonging to the order Pleuronectina, the family Paralichthydae, which are useful in the growth promotion for fishes, by genetic engineering using cloned genes.
5370872 ESCHERICHIA COLIOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINE Cryz Stanley J; Furer Emil Bolligen, SWITZERLAND Assigned to Swiss Serum and Vaccine Institute Berne
thereof, inch as A.T.C.C. 13060 and A.T.C.C. 13869, respectively, are useful in the treatment of diarrhea in domesticated animals.
~7~28 HEPATITIS C VIRUS ISOLATES Miyamm-a Tatsu; Salto Izumi; Houghton Michael; Weiner Amy J; Han Jang; Kolberg Janice; Cha Tai-An; Irvine Bruce D Tokyo, JAPA~ Assigned to Cl~iron Corporation; The Director General of the National Institute of Health of Japan
The present invention relates to a method of producing an E. coil vaccine and to the vaccine produced thereby. The method involves purifying lipopolysaccbaride from E. coil expressing complete O-polysaccharide sidechalns:isolating the O-polysaccharide region of the lipopolysaccharide molecule by hydrolysis in dilute acetic acid and purifying it essentially free of lipid A; and covalently coupling lipid A-free Opolysaccharide via at least one hydroxyl or carboxyl group of the polysaccharide to a carrier protein. Polyvalent vaccines are prepared by combining two or more monovalent vaccines for different serotypes prepared according to the present invention. The present also relates to conjugates used in the vaccines. The conjugates of the present invention are the O-polysaccharide region of an E. coli lipoplysaccharide molecule covalently coupled to a carrier protein.
Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.
5372810
Cytokine receptors for tumor necrosis factor e which are found on microorganisms may, if bound with exogenous TNF alpha, enhance the response of natural killer cells activated by the microorganisms, or increase TNF alpha production by peripheral blood lymphocytes treated with the microorganisms. Microorganisms with receptor-bound exogenous ~ alpha have enhanced cellular invasion ability which may change the immune response thereto. Clinical and pharrmceutical applications of these discoveries are provided.
COMPOSITION FOR THE PREVENTION AND TREATMENT OF DIARRHEA IN LIVESTOCK Onishi Norimasa; Yamashiro Akihiro Kawasaki, JAPAN Assigned to Ajinomoto Company Inc A composition and method for the prevention and treatment of diarrhea in domesticated animals. comprising sterilized cells of aerobic bacteria belonging to the genus Bacillus, Brevibaclcrium, Corynebacterium, Escherichia, Lactohacillus, Streptococcus, or Streptomyces, a cell homogenate of said sterilized cells, a cell wall component-containing fraction of said homogenate or mixtures thereof. In particular species of Corynebacterium glutamicum and Brevibacterium iac~ofermentom as well as stralus
~7~23 METHOD OF USING CYTOKINE RECEPTORS ON MICROORGANISM Klimpel Gary; Niesel David Sante Fe, TX, UNITED STATES Assigned to Board of Regents The University of Texas System
~7~24 MULTIVALENT FELV-INFECTED FELINE VACCINE Keisey William H; Bass Edmund P Alameda, CA, UNITED STATES Assigned to Miles Inc
PATENT ABSTRACTS
804
A multivalent FeLV-infected feline vaccine composed of (1) a small but immunologically effective amount of inactivated feline leukemia virus; (2) a small but effective amount of an inactivated virus selected from the group consisting of Feline Rhinotracbeitis Virus, Feline Calici Virus and Feline Panleukopenia Virus; and (3) a pharmaceutically acceptable immunologica adjuvant. Components (1) and (2) may be inactivated by any of the known techniques. The inactivated feline leukemia virus must be from subgroup A and is the Rickard isolate of the virus designated FeLV-AR1. This combination vaccine is effective in preventing Viremia, leukemiaassociated syndromes, and deaths in cats caused by Feline Leukemia Virus, Feline Rhinotracheitis Virus, Feline Calici Virus and Feline Panleukemia Virus infections. 5374426 ROTAVIRUS NUCLEOCAPSID PROTEIN VP6 IN VACCINE COMPOSITIONS Sabara Marta; Frenchick Patrick J; Mullin-Reedy Kerry F Saskatoon, CANADA Assigned to University of Snskatehewan Immunological carrier complexes are provided utilizing the VP6 polypeptide from rotavirus as the carrier molecule. Also provided are methods of binding epitope-bearing molecules (e.g., hapteus) to the VP6 carrier molecule through binding peptides. The VP6 carrier can be a VP6 monomer, oligomer, or a particle.
5374431
helix surface. The apolar stripes allow the polypeptide chains to aggregate into superhelical structures and the polar stripes allow interclmin crosslinking within and between the superhelical structures.
5374518 MONOCLONAL ANTIBODY FOR DIFFERENTIATING HIV-2 FROM HIM-1 SEROPOSITIVE INDIVIDUALS Hunt Jeffrey C; Satin Virender; Devare Sushil; Tribby Ilse I; Desai Suresh M; Casey James M Lindenhurst, IL, UNITED STATES Assigned to Abbott Laboratories A mouse monoclonal antibody is provided which detects HIV-2 seropositive individuals and differentiates them from HIV-1 seropositive individuals. The monoclonal antibody is specific for an epitope of HIV-2 gp41 which lies outside the characterized immunodominant region. The epitope recognized by the monocional antibody has the amino acid sequence HTTVPW.
5374549 PROCESS OF ENRICHING ADHERENT CD4+ T CELLS FROM MONOCYTE DEPLETED PERIPHERAL BLOOD MONONUCLEAR CELLS WITH INTERLEUKIN 2 AND INTERLEUKIN 4
SYNTHETIC BIOADHESIVE Pang Roy H; Cohen Charles M; Keck Peter C Medway, MA, UNITED STATES Assigned to Creative Biomolecules Inc This invention pertains to a synthetic adhesive composition for use in aqueous environments. The composition comprises polypeptide chains having an alpha-helical structure in aqueous environments and capable of cohesive and adhesive interactions. The polypeptide chains comprise polar and apolar amino acids, the apolar and polar amino acids being arranged to define apolar and polar vertical spiraling stripes on the
Leung Kam H Brookhaven, PA, UNITED STATES Assigned to Terumo Corporation Peripheral blood monouuclear cells (PBMC) are treated to deplete monocytes and the remaining cells are cultured in a medium containing interleukin-2 0L-2) and interleukin-4 (IL-4). Nouadhereut cells are removed and discarded, and adherent cells are further cultured in a medium of IL-2 and IL-4 which expands the CD4+ T cells population of the PBMC. The expanded, enriched CD4+T cells can be placed in a pharmaceutically acceptable carrier and administered to a mammal with IL-2 to treat a tumor.
PATENT ABSTRACTS belonging to the order Pleuronectina, the family Paralichthydae, which are useful in the growth promotion for fishes, by genetic engineering using cloned genes.
5370872 ESCHERICHIA COLIOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINE Cryz Stanley J; Furer Emil Bolligen, SWITZERLAND Assigned to Swiss Serum and Vaccine Institute Berne
thereof, inch as A.T.C.C. 13060 and A.T.C.C. 13869, respectively, are useful in the treatment of diarrhea in domesticated animals.
~7~28 HEPATITIS C VIRUS ISOLATES Miyamm-a Tatsu; Salto Izumi; Houghton Michael; Weiner Amy J; Han Jang; Kolberg Janice; Cha Tai-An; Irvine Bruce D Tokyo, JAPA~ Assigned to Cl~iron Corporation; The Director General of the National Institute of Health of Japan
The present invention relates to a method of producing an E. coil vaccine and to the vaccine produced thereby. The method involves purifying lipopolysaccbaride from E. coil expressing complete O-polysaccharide sidechalns:isolating the O-polysaccharide region of the lipopolysaccharide molecule by hydrolysis in dilute acetic acid and purifying it essentially free of lipid A; and covalently coupling lipid A-free Opolysaccharide via at least one hydroxyl or carboxyl group of the polysaccharide to a carrier protein. Polyvalent vaccines are prepared by combining two or more monovalent vaccines for different serotypes prepared according to the present invention. The present also relates to conjugates used in the vaccines. The conjugates of the present invention are the O-polysaccharide region of an E. coli lipoplysaccharide molecule covalently coupled to a carrier protein.
Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.
5372810
Cytokine receptors for tumor necrosis factor e which are found on microorganisms may, if bound with exogenous TNF alpha, enhance the response of natural killer cells activated by the microorganisms, or increase TNF alpha production by peripheral blood lymphocytes treated with the microorganisms. Microorganisms with receptor-bound exogenous ~ alpha have enhanced cellular invasion ability which may change the immune response thereto. Clinical and pharrmceutical applications of these discoveries are provided.
COMPOSITION FOR THE PREVENTION AND TREATMENT OF DIARRHEA IN LIVESTOCK Onishi Norimasa; Yamashiro Akihiro Kawasaki, JAPAN Assigned to Ajinomoto Company Inc A composition and method for the prevention and treatment of diarrhea in domesticated animals. comprising sterilized cells of aerobic bacteria belonging to the genus Bacillus, Brevibaclcrium, Corynebacterium, Escherichia, Lactohacillus, Streptococcus, or Streptomyces, a cell homogenate of said sterilized cells, a cell wall component-containing fraction of said homogenate or mixtures thereof. In particular species of Corynebacterium glutamicum and Brevibacterium iac~ofermentom as well as stralus
~7~23 METHOD OF USING CYTOKINE RECEPTORS ON MICROORGANISM Klimpel Gary; Niesel David Sante Fe, TX, UNITED STATES Assigned to Board of Regents The University of Texas System
~7~24 MULTIVALENT FELV-INFECTED FELINE VACCINE Keisey William H; Bass Edmund P Alameda, CA, UNITED STATES Assigned to Miles Inc
PATENT ABSTRACTS
804
A multivalent FeLV-infected feline vaccine composed of (1) a small but immunologically effective amount of inactivated feline leukemia virus; (2) a small but effective amount of an inactivated virus selected from the group consisting of Feline Rhinotracbeitis Virus, Feline Calici Virus and Feline Panleukopenia Virus; and (3) a pharmaceutically acceptable immunologica adjuvant. Components (1) and (2) may be inactivated by any of the known techniques. The inactivated feline leukemia virus must be from subgroup A and is the Rickard isolate of the virus designated FeLV-AR1. This combination vaccine is effective in preventing Viremia, leukemiaassociated syndromes, and deaths in cats caused by Feline Leukemia Virus, Feline Rhinotracheitis Virus, Feline Calici Virus and Feline Panleukemia Virus infections. 5374426 ROTAVIRUS NUCLEOCAPSID PROTEIN VP6 IN VACCINE COMPOSITIONS Sabara Marta; Frenchick Patrick J; Mullin-Reedy Kerry F Saskatoon, CANADA Assigned to University of Snskatehewan Immunological carrier complexes are provided utilizing the VP6 polypeptide from rotavirus as the carrier molecule. Also provided are methods of binding epitope-bearing molecules (e.g., hapteus) to the VP6 carrier molecule through binding peptides. The VP6 carrier can be a VP6 monomer, oligomer, or a particle.
5374431
helix surface. The apolar stripes allow the polypeptide chains to aggregate into superhelical structures and the polar stripes allow interclmin crosslinking within and between the superhelical structures.
5374518 MONOCLONAL ANTIBODY FOR DIFFERENTIATING HIV-2 FROM HIM-1 SEROPOSITIVE INDIVIDUALS Hunt Jeffrey C; Satin Virender; Devare Sushil; Tribby Ilse I; Desai Suresh M; Casey James M Lindenhurst, IL, UNITED STATES Assigned to Abbott Laboratories A mouse monoclonal antibody is provided which detects HIV-2 seropositive individuals and differentiates them from HIV-1 seropositive individuals. The monoclonal antibody is specific for an epitope of HIV-2 gp41 which lies outside the characterized immunodominant region. The epitope recognized by the monocional antibody has the amino acid sequence HTTVPW.
5374549 PROCESS OF ENRICHING ADHERENT CD4+ T CELLS FROM MONOCYTE DEPLETED PERIPHERAL BLOOD MONONUCLEAR CELLS WITH INTERLEUKIN 2 AND INTERLEUKIN 4
SYNTHETIC BIOADHESIVE Pang Roy H; Cohen Charles M; Keck Peter C Medway, MA, UNITED STATES Assigned to Creative Biomolecules Inc This invention pertains to a synthetic adhesive composition for use in aqueous environments. The composition comprises polypeptide chains having an alpha-helical structure in aqueous environments and capable of cohesive and adhesive interactions. The polypeptide chains comprise polar and apolar amino acids, the apolar and polar amino acids being arranged to define apolar and polar vertical spiraling stripes on the
Leung Kam H Brookhaven, PA, UNITED STATES Assigned to Terumo Corporation Peripheral blood monouuclear cells (PBMC) are treated to deplete monocytes and the remaining cells are cultured in a medium containing interleukin-2 0L-2) and interleukin-4 (IL-4). Nouadhereut cells are removed and discarded, and adherent cells are further cultured in a medium of IL-2 and IL-4 which expands the CD4+ T cells population of the PBMC. The expanded, enriched CD4+T cells can be placed in a pharmaceutically acceptable carrier and administered to a mammal with IL-2 to treat a tumor.